Cargando…

Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. Validated laboratory parameters for RA diagnosis are higher blood levels of rheumatoid factor IgM (IgM-RF), anti-citrullinated protein autoantibodies (ACPA), C-reactive protein (CRP) levels and eryth...

Descripción completa

Detalles Bibliográficos
Autores principales: Arntz, Onno J., Pieters, Bartijn C. H., Thurlings, Rogier M., Wenink, Mark H., van Lent, Peter L. E. M., Koenders, Marije I., van den Hoogen, Frank H. J., van der Kraan, Peter M., van de Loo, Fons A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215817/
https://www.ncbi.nlm.nih.gov/pubmed/30420853
http://dx.doi.org/10.3389/fimmu.2018.02388
_version_ 1783368209701797888
author Arntz, Onno J.
Pieters, Bartijn C. H.
Thurlings, Rogier M.
Wenink, Mark H.
van Lent, Peter L. E. M.
Koenders, Marije I.
van den Hoogen, Frank H. J.
van der Kraan, Peter M.
van de Loo, Fons A. J.
author_facet Arntz, Onno J.
Pieters, Bartijn C. H.
Thurlings, Rogier M.
Wenink, Mark H.
van Lent, Peter L. E. M.
Koenders, Marije I.
van den Hoogen, Frank H. J.
van der Kraan, Peter M.
van de Loo, Fons A. J.
author_sort Arntz, Onno J.
collection PubMed
description Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. Validated laboratory parameters for RA diagnosis are higher blood levels of rheumatoid factor IgM (IgM-RF), anti-citrullinated protein autoantibodies (ACPA), C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR). Clinical parameters used are the number of tender (TJC) and swollen joints (SJC) and the global patient visual analog score (VAS). To determine disease remission in patients a disease activity score (DAS28) can be calculated based on SJC, TJC, VAS, and ESR (or alternatively CRP). However, subtle and better predictive changes to follow treatment responses in individual patients cannot be measured by the above mentioned parameters nor by measuring cytokine levels in blood. As extracellular vesicles (EVs) play a role in intercellular communication and carry a multitude of signals we set out to determine their value as a biomarker for disease activity. EVs were isolated from platelet-free plasma of 41 RA patients and 24 healthy controls (HC) by size exclusion chromatography (SEC). We quantified the particle and protein concentration, using NanoSight particle tracking analysis and micro-BCA, respectively, and observed no differences between RA patients and HC. In plasma of 28 out of 41 RA patients IgM-RF was detectable by ELISA, and in 13 out of these 28 seropositive RA patients (RF(+)RA) IgM-RF was also detected on their isolated pEVs (IgM-RF(+)). In seronegative RA patients (RF(−)RA) we did not find any RF present on pEVs. When comparing disease parameters we found no differences between RF(+)RA and RF(−)RA patients, except for increased ESR levels in RF(+)RA patients. However, RF(+)RA patients with IgM-RF(+) pEVs showed significantly higher levels of CRP and ESR and also VAS and DAS28 were significantly increased compared to RA(+) patients without IgM-RF(+) pEVs. This study shows for the first time the presence of IgM-RF on pEVs in a proportion of RF(+)RA patients with a higher disease activity.
format Online
Article
Text
id pubmed-6215817
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62158172018-11-12 Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity Arntz, Onno J. Pieters, Bartijn C. H. Thurlings, Rogier M. Wenink, Mark H. van Lent, Peter L. E. M. Koenders, Marije I. van den Hoogen, Frank H. J. van der Kraan, Peter M. van de Loo, Fons A. J. Front Immunol Immunology Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. Validated laboratory parameters for RA diagnosis are higher blood levels of rheumatoid factor IgM (IgM-RF), anti-citrullinated protein autoantibodies (ACPA), C-reactive protein (CRP) levels and erythrocyte sedimentation rate (ESR). Clinical parameters used are the number of tender (TJC) and swollen joints (SJC) and the global patient visual analog score (VAS). To determine disease remission in patients a disease activity score (DAS28) can be calculated based on SJC, TJC, VAS, and ESR (or alternatively CRP). However, subtle and better predictive changes to follow treatment responses in individual patients cannot be measured by the above mentioned parameters nor by measuring cytokine levels in blood. As extracellular vesicles (EVs) play a role in intercellular communication and carry a multitude of signals we set out to determine their value as a biomarker for disease activity. EVs were isolated from platelet-free plasma of 41 RA patients and 24 healthy controls (HC) by size exclusion chromatography (SEC). We quantified the particle and protein concentration, using NanoSight particle tracking analysis and micro-BCA, respectively, and observed no differences between RA patients and HC. In plasma of 28 out of 41 RA patients IgM-RF was detectable by ELISA, and in 13 out of these 28 seropositive RA patients (RF(+)RA) IgM-RF was also detected on their isolated pEVs (IgM-RF(+)). In seronegative RA patients (RF(−)RA) we did not find any RF present on pEVs. When comparing disease parameters we found no differences between RF(+)RA and RF(−)RA patients, except for increased ESR levels in RF(+)RA patients. However, RF(+)RA patients with IgM-RF(+) pEVs showed significantly higher levels of CRP and ESR and also VAS and DAS28 were significantly increased compared to RA(+) patients without IgM-RF(+) pEVs. This study shows for the first time the presence of IgM-RF on pEVs in a proportion of RF(+)RA patients with a higher disease activity. Frontiers Media S.A. 2018-10-29 /pmc/articles/PMC6215817/ /pubmed/30420853 http://dx.doi.org/10.3389/fimmu.2018.02388 Text en Copyright © 2018 Arntz, Pieters, Thurlings, Wenink, van Lent, Koenders, van den Hoogen, van der Kraan and van de Loo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Arntz, Onno J.
Pieters, Bartijn C. H.
Thurlings, Rogier M.
Wenink, Mark H.
van Lent, Peter L. E. M.
Koenders, Marije I.
van den Hoogen, Frank H. J.
van der Kraan, Peter M.
van de Loo, Fons A. J.
Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
title Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
title_full Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
title_fullStr Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
title_full_unstemmed Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
title_short Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
title_sort rheumatoid arthritis patients with circulating extracellular vesicles positive for igm rheumatoid factor have higher disease activity
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6215817/
https://www.ncbi.nlm.nih.gov/pubmed/30420853
http://dx.doi.org/10.3389/fimmu.2018.02388
work_keys_str_mv AT arntzonnoj rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT pietersbartijnch rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT thurlingsrogierm rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT weninkmarkh rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT vanlentpeterlem rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT koendersmarijei rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT vandenhoogenfrankhj rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT vanderkraanpeterm rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity
AT vandeloofonsaj rheumatoidarthritispatientswithcirculatingextracellularvesiclespositiveforigmrheumatoidfactorhavehigherdiseaseactivity